Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of BSCT Ointment in Basal Cell Carcinoma
NCT02587819Phase 1Completed
- Sponsor
- Biosceptre
- Start
- May 2013
- Primary completion
- Oct 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of BSCT in basal cell carcinoma (BCC), sponsored by Biosceptre. Primary endpoints: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) at 8 weeks, Serum Concentration of Total Sheep IgG at 28 days and 1 more. Started May 2013; status: completed.
02
Drugs
BSCT
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT02587819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02587819.